198 related articles for article (PubMed ID: 33840347)
21. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220
[TBL] [Abstract][Full Text] [Related]
22. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.
Miyakawa K; Jeremiah SS; Ohtake N; Matsunaga S; Yamaoka Y; Nishi M; Morita T; Saji R; Nishii M; Kimura H; Hasegawa H; Takeuchi I; Ryo A
J Mol Cell Biol; 2020 Nov; 12(12):987-990. PubMed ID: 32931563
[No Abstract] [Full Text] [Related]
23. Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring.
Cristiano A; Pieri M; Sarubbi S; Pelagalli M; Calugi G; Tomassetti F; Bernardini S; Nuccetelli M
Clin Immunol; 2022 Jan; 234():108918. PubMed ID: 34971839
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a rapid semiquantitative lateral flow assay for the prediction of serum neutralizing activity against SARS-CoV-2 variants.
Hirabidian M; Bocket L; Demaret J; Vuotto F; Rabat A; Faure K; Labalette M; Hober D; Lefevre G; Alidjinou EK
J Clin Virol; 2022 Oct; 155():105268. PubMed ID: 35998394
[TBL] [Abstract][Full Text] [Related]
25. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
26. Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.
Patel EU; Bloch EM; Clarke W; Hsieh YH; Boon D; Eby Y; Fernandez RE; Baker OR; Keruly M; Kirby CS; Klock E; Littlefield K; Miller J; Schmidt HA; Sullivan P; Piwowar-Manning E; Shrestha R; Redd AD; Rothman RE; Sullivan D; Shoham S; Casadevall A; Quinn TC; Pekosz A; Tobian AAR; Laeyendecker O
J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33139419
[TBL] [Abstract][Full Text] [Related]
27. Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants.
Morinaga Y; Tani H; Terasaki Y; Nomura S; Kawasuji H; Shimada T; Igarashi E; Saga Y; Yoshida Y; Yasukochi R; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Fujimura T; Ishida Y; Oishi K; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056021. PubMed ID: 34851163
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.
Matusali G; Colavita F; Lapa D; Meschi S; Bordi L; Piselli P; Gagliardini R; Corpolongo A; Nicastri E; Antinori A; Ippolito G; Capobianchi MR; Castilletti C; Inmi Covid-Laboratory Team
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920222
[TBL] [Abstract][Full Text] [Related]
29. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
30. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
[TBL] [Abstract][Full Text] [Related]
31. The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody.
Li Y; He J; Zhang Y; Liang D; Zhang J; Ji R; Wu Y; Su Z; Ke C; Xu N; Tang Y; Xu J
Front Cell Infect Microbiol; 2023; 13():1203625. PubMed ID: 37736103
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2.
Müller K; Girl P; von Buttlar H; Dobler G; Wölfel R
J Virol Methods; 2021 Jun; 292():114122. PubMed ID: 33705832
[TBL] [Abstract][Full Text] [Related]
33. Searching for escape-resistant anti-SARS-CoV-2 neutralizing antibodies.
Mahla RS; Dustin LB
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35072657
[TBL] [Abstract][Full Text] [Related]
34. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness.
Jeewandara C; Jayathilaka D; Gomes L; Wijewickrama A; Narangoda E; Idampitiya D; Guruge D; Wijayamuni R; Manilgama S; Ogg GS; Tan CW; Wang LF; Malavige GN
Sci Rep; 2021 Jan; 11(1):2062. PubMed ID: 33479465
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous measurement of multiple variant-specific SARS-CoV-2 neutralizing antibodies with a multiplexed flow cytometric assay.
Liu H; Varvel S; Chen G; McConnell J; Caffrey R; Galdzicka M; Shabahang S
Front Immunol; 2022; 13():1039163. PubMed ID: 36505453
[TBL] [Abstract][Full Text] [Related]
37. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
Cheng HL; Lim SM; Jia H; Chen MW; Ng SY; Gao X; Somani J; Sengupta S; Tay DMY; Chua PWL; R A; Ling SYH; McBee ME; Young BE; Sikes HD; Preiser PR
Microbiol Spectr; 2022 Oct; 10(5):e0225722. PubMed ID: 36069616
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
Favresse J; Gillot C; Di Chiaro L; Eucher C; Elsen M; Van Eeckhoudt S; David C; Morimont L; Dogné JM; Douxfils J
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372570
[TBL] [Abstract][Full Text] [Related]
40. Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
Valcourt EJ; Manguiat K; Robinson A; Lin YC; Abe KT; Mubareka S; Shigayeva A; Zhong Z; Girardin RC; DuPuis A; Payne A; McDonough K; Wang Z; Gasser R; Laumaea A; Benlarbi M; Richard J; Prévost J; Anand SP; Dimitrova K; Phillipson C; McGeer A; Gingras AC; Liang C; Petric M; Sekirov I; Morshed M; Finzi A; Drebot M; Wood H
Microbiol Spectr; 2021 Dec; 9(3):e0088621. PubMed ID: 34787495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
